HC Wainwright Issues Positive Outlook for argenex Earnings

argenex SE (NASDAQ:ARGX) – Investment analysts at HC Wainwright raised their Q3 2026 earnings estimates for argenex in a research report issued to clients and investors on Friday, July 24th. HC Wainwright analyst D. Tsao now expects that the company will earn $6.51 per share for the quarter, up from their prior estimate of $6.48. HC Wainwright currently has a “Buy” rating and a $940.00 price objective on the stock. The consensus estimate for argenex’s current full-year earnings is $27.28 per share. HC Wainwright also issued estimates for argenex’s Q1 2027 earnings at $7.57 EPS, Q2 2027 earnings at $8.41 EPS, Q3 2027 earnings at $8.86 EPS and Q4 2027 earnings at $9.53 EPS.

Other equities analysts also recently issued reports about the company. Morgan Stanley lifted their target price on argenex from $1,170.00 to $1,180.00 and gave the company an “overweight” rating in a research note on Wednesday, June 24th. Citigroup raised their price target on argenex from $1,152.00 to $1,182.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. Robert W. Baird boosted their price objective on argenex from $867.00 to $932.00 and gave the company a “neutral” rating in a research report on Monday. Citizens Jmp reduced their price objective on argenex from $944.00 to $932.00 and set a “market outperform” rating for the company in a research report on Friday, July 24th. Finally, Wall Street Zen upgraded argenex from a “hold” rating to a “buy” rating in a research note on Saturday. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, argenex presently has a consensus rating of “Moderate Buy” and an average target price of $1,056.89.

argenex Stock Down 1.9%

ARGX opened at $872.23 on Monday. The company’s 50-day moving average price is $872.02 and its 200 day moving average price is $816.17. argenex has a fifty-two week low of $590.78 and a fifty-two week high of $953.58. The firm has a market cap of $54.57 billion, a price-to-earnings ratio of 33.50, a price-to-earnings-growth ratio of 1.16 and a beta of 0.45.

argenex (NASDAQ:ARGX) last posted its quarterly earnings results on Tuesday, July 21st. The company reported $7.32 EPS for the quarter, beating the consensus estimate of $5.86 by $1.46. argenex had a net margin of 32.19% and a return on equity of 43.59%. The business had revenue of $1.54 billion during the quarter, compared to analyst estimates of $1.45 billion.

Institutional Investors Weigh In On argenex

Several large investors have recently made changes to their positions in ARGX. Oppenheimer & Co. Inc. increased its holdings in argenex by 2.8% during the 4th quarter. Oppenheimer & Co. Inc. now owns 442 shares of the company’s stock valued at $372,000 after purchasing an additional 12 shares in the last quarter. Valeo Financial Advisors LLC boosted its stake in argenex by 0.9% in the fourth quarter. Valeo Financial Advisors LLC now owns 1,372 shares of the company’s stock worth $1,153,000 after purchasing an additional 12 shares in the last quarter. CI Investments Inc. boosted its stake in argenex by 2.6% in the fourth quarter. CI Investments Inc. now owns 469 shares of the company’s stock worth $394,000 after purchasing an additional 12 shares in the last quarter. Allworth Financial LP grew its holdings in shares of argenex by 12.7% during the fourth quarter. Allworth Financial LP now owns 115 shares of the company’s stock worth $97,000 after purchasing an additional 13 shares during the last quarter. Finally, WPG Advisers LLC increased its stake in shares of argenex by 17.8% in the first quarter. WPG Advisers LLC now owns 86 shares of the company’s stock valued at $63,000 after buying an additional 13 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

Key argenex News

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Strategic pipeline expansion: argenx agreed to acquire Forte Biosciences for $77 per share in cash, adding FB102, an anti-CD122 antibody being studied in vitiligo and celiac disease. Management cited encouraging Phase 1b data, significant unmet need and “pipeline-in-a-product” potential. argenx acquisition announcement
• Positive Sentiment: Analysts remain constructive: Wedbush raised its price target to $1,050 and maintained an “outperform” rating. HC Wainwright kept a “Buy” rating and increased its long-term EPS forecasts, including estimates for 2027 through 2030, indicating expectations for substantial earnings growth. Wedbush price target report
• Positive Sentiment: Strong operating momentum: argenx recently exceeded quarterly expectations with adjusted earnings of $7.32 per share versus a $5.86 consensus estimate and revenue of $1.54 billion versus expectations of $1.45 billion. This supports the investment case despite the acquisition spending.
• Neutral Sentiment: Valuation views are mixed: recent commentary describes ARGX as fairly valued with modest upside, while another analysis suggests the stock could be roughly 15% above fair value after incorporating the Forte transaction. Baird raised its target to $932 but retained a “neutral” rating.
• Negative Sentiment: Acquisition and execution risks: the Forte transaction requires argenx to commit approximately $2.2 billion before FB102’s clinical and commercial success is established. In addition, Kahn Swick & Foti is investigating whether Forte shareholders are receiving adequate consideration and whether the sale process was appropriate, potentially adding legal and deal-completion uncertainty. Forte transaction investigation

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.